Butyrate inhibits histone deacetylase 2 expression to alleviate liver fibrosis in biliary atresia
Butyrate may improve liver fibrosis in BA by regulating HDAC2 expression and modulating the IL-6/STAT3 pathway. Therefore, butyrate could serve as a promising therapeutic option for mitigating liver fibrosis in BA.
Authors
- Shujian Zhang (ORCID: https://orcid.org/0000-0003-3216-722X)
- Yan Sun (ORCID: https://orcid.org/0000-0001-9945-2557)
- Xiaodan Xu (ORCID: https://orcid.org/0000-0001-8338-1600)
- Jiayinaxi Musha
- Shaowen Liu (ORCID: https://orcid.org/0000-0002-0351-6868)
- Tengfei Li (ORCID: https://orcid.org/0000-0001-6142-3865)
- Li Zhao (ORCID: https://orcid.org/0000-0001-5600-5087)
- Yilin Zhao (ORCID: https://orcid.org/0009-0006-7723-6945)
- Xueting Wang (ORCID: https://orcid.org/0000-0001-6172-7148)
- Liang Ge (ORCID: https://orcid.org/0000-0003-3565-3741)
- Jianghua Zhan (ORCID: https://orcid.org/0000-0002-5257-8619)
Institutions
- Yili Friendship Hospital (CN)
- Tianjin Children's Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- BMC Pediatrics
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1186/s12887-025-05635-3
- Citations
- 7
- Primary Topic
- Pediatric Hepatobiliary Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 14.04